Can determination of circulating endothelial cells and serum caspase-cleaved CK18 Predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy?

• Verfasst von: Chu, Tian-Qing [VerfasserIn]
• Verfasst von: Du, Wei-Dong [VerfasserIn]
• Titel: Can determination of circulating endothelial cells and serum caspase-cleaved CK18 Predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy?
• Titelzusatz: a retrospective study
• Verf.angabe: Tian-Qing Chu, Hao Ding, David H. Garfield, Ai-Qin Gu, Jun Pei, Wei-Dong Du and Bao-Hui Han
• Jahr: 2015
• Jahr des Originals: 2012
• Umfang: 9 S.
• Fussnoten: Available online 20 November 2015 ; Gesehen am 23.07.2018
• Titel Quelle: Enthalten in: Journal of thoracic oncology
• Ort Quelle: Amsterdam : Elsevier, 2006
• Jahr Quelle: 2012
• Band/Heft Quelle: 7(2012), 12, Seite 1781-1789
• ISSN Quelle: 1556-1380
• DOI: doi:10.1097/JTO.0b013e3182725fe0
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Biomarker
• Sach-SW: Circulating endothelial cells
• Sach-SW: Cytokeratins
• Sach-SW: Endostatin
• Sach-SW: Non-small-cell lung cancer
• K10plus-PPN: 1577829506

Abstract

Introduction: Early prediction of the efficacy of a combination of an antiangiogenic drug with cytotoxic chemotherapy is a significant challenge. In that regard, circulating endothelial cells (CECs) and cytokeratins (CKs) seem to reflect their roles in both tumor angiogenesis and tumor cell death.Methods: Patients with advanced, previously untreated non-small-cell lung cancer were randomly assigned to an endostatin treatment group (paclitaxel + carboplatin + endostatin) and a control group (paclitaxel + carboplatin + placebo). A total of 122 patients were evaluated, of whom 107 had measurements of blood CECs, CK8, caspase-cleaved CK18 (ccCK18), and uncleaved CK18 (CK18) before and at weeks 3 and 6 of treatment, respectively.Results: Higher baseline CECs in patients with a tumor response (partial remission + stable disease, p = 0.002 for the entire group; p = 0.000 for the treatment group) were observed. The number of CECs decreased significantly after endostatin treatment (p = 0.000), whereas CK levels increased. Increased levels of ccCK18 and CK18, but not CK8, reached significance (p = 0.001 and p = 0.048, respectively) when compared with the baseline. Tumor response showed a strong correlation with reduction of CECs (p = 0.000) and increase of ccCK18 (p = 0.040) after endostatin therapy. Cutoff values of changes of CECs and ccCK18 for prediction of survival were 0.58/μl and 19.6 ng/ml, respectively. Reduction of CECs and increase of ccCK18 significantly correlated with longer median survival (p = 0.013 and p = 0.016 for progression-free survival; p = 0.009 and p = 0.012 for overall survival, respectively).Conclusions: CECs and CKs could be biomarkers for selecting patients with non-small-cell lung cancer who will benefit from treatment with endostatin in combination with paclitaxel plus carboplatin.